Comparing DOAC and warfarin outcomes in an obese population using the ‘real-world’ Michigan Anticoagulation Quality Improvement Initiative (MAQI<sup>2</sup>) registry
There is a higher rate of bleeding in severely obese patients with VTE and AF treated with DOACs compared to warfarin, without a difference in secondary outcomes. Further studies to compare the anticoagulant classes and understand bleeding drivers in this population are needed.
Authors
- Thane Feldeisen (ORCID: https://orcid.org/0000-0003-2515-6338)
- Geoffrey D. Barnes (ORCID: https://orcid.org/0000-0002-6532-8440)
- Mona A. Ali (ORCID: https://orcid.org/0000-0003-2416-6702)
- Xiaowen Kong (ORCID: https://orcid.org/0000-0003-4548-3600)
- James B. Froehlich (ORCID: https://orcid.org/0000-0003-2327-8235)
- Scott S. Kaatz (ORCID: https://orcid.org/0000-0002-3080-3328)
- Nelish Ardeshna
- Brian Haymart
Institutions
- Rush University Medical Center (US)
- University of Michigan (US)
- Henry Ford Hospital (US)
- Michigan Medicine (US)
- Beaumont Hospital, Royal Oak (US)
Publication Details
- Journal
- Vascular Medicine
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1177/1358863x241264478
- Citations
- 3
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.21
Funders
- Blue Cross Blue Shield of Michigan Foundation